| answer text |
<p>The Department is doing everything appropriate to prepare for leaving the European
Union. We want to reassure patients that our plans should ensure the uninterrupted
supply of medicines and medical products, including those used for the treatment of
epilepsy, once we have left the EU.</p><p>The Department, as part of our EU exit preparations,
is implementing a multi-layered approach to mitigate potential disruption to supply,
which consists of stockpiling where possible, securing freight capacity, changing
or clarifying regulatory requirements, procuring additional warehousing, working closely
with industry to improve trader readiness and putting in place the National Supply
Disruption Response to manage potential shortages. Further details can be found at
the following link:</p><p><a href="https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans"
target="_blank">https://www.gov.uk/government/news/medicines-and-medical-products-supply-government-updates-no-deal-brexit-plans</a></p><p>We
have been working closely with suppliers to monitor over 300 different epilepsy medicines
provided by almost 50 companies and we are pleased to see many are holding stockpiles
far beyond the six weeks’ additional buffer we requested. We also know that the vast
majority of those suppliers with lower levels of stockpiles are taking action to re-route
their supply chains away from the short straits crossings where applicable.</p><p>
</p><p> </p>
|
|
